Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 137 |
|
|||||
| News | - | ||||||
| Day High | 26.16 | Low High |
|||||
| Day Low | 26.16 | ||||||
| Company Name | Etf Ticker Symbol | Market | Type |
|---|---|---|---|
| Virtus LifeSci Biotech Clinical Trials ETF | BBC | AMEX | Exchange Traded Fund |
| Price Change | Change Percent | Etf Price | Last Traded
|
|
|---|---|---|---|---|
| -0.0922 | -0.35% | 26.16 | 11:31:31 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 26.16 | 26.16 | 26.16 | 26.2522 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 7 | 137 | - | 16.88 - 31.99 |
| Last Trade Time | Type | Quantity | Etf Price | Currency |
|---|---|---|---|---|
| 11:08:57 | 40 | 26.2717 | USD |
Virtus LifeSci Biotech Clinical Trials ETF Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 11.81M | 450.00k | - | 132k | -4.06M | -9.03 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
News Virtus LifeSci Biotech C...
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
BBC Historical
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 25.28 | 26.46 | 24.512 | 25.60 | 1,225 | 0.88 | 3.48% |
| 1 Month | 28.35 | 28.35 | 24.512 | 27.07 | 2,908 | -2.19 | -7.72% |
| 3 Months | 25.87 | 31.99 | 24.512 | 28.69 | 4,269 | 0.29 | 1.12% |
| 6 Months | 16.91 | 31.99 | 16.91 | 26.09 | 3,269 | 9.25 | 54.70% |
| 1 Year | 23.22 | 31.99 | 16.88 | 25.19 | 2,269 | 2.94 | 12.66% |
| 3 Years | 50.78 | 52.18 | 16.88 | 32.11 | 3,361 | -24.62 | -48.48% |
| 5 Years | 28.30 | 62.60 | 16.88 | 37.69 | 9,138 | -2.14 | -7.56% |
| The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering (lead drug) that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval. |
